The importance of identifying CUP subsets

Carcinoma of an Unknown Primary Site

Volumn , Issue , 2006, Pages 37-48

  Pavlidis, Nicholas ^a   Merrouche, Yacine ^b  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b Institut de Cancerologie de la Loire   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 38749084460     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (54)

1. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review. National Cancer Institute, 1999.
2. Levi F, Te VC, Erler G, Randimbison L, La Vecchia C. Epidemiology of unknown primary tumors. Eur J Cancer 2002; 38:1810-1812.
3. Van de Wouw AJ, Janssen-Heijnen MLG, Coebergh JWW, Hillen HF. Epidemiology of unknown primary tumors; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer 2002; 38:409-113.
4. Frost P, Raber MN, Abbruzzese JL. Unknown primary tumors as a unique clinical and biologic entity: a hypothesis. Cancer Bull 1989; 41:139-141.
5. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 1995; 13:2094-2103.
6. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003; 39: 1990-2005.
7. Nystrom JS, Weiner JM, Hellelfinger-Juttner J, Irwin LE, Bateman JR, Wolf RM. Metastatic and histologic presentation in unknown primary cancer. Semin Oncol 1977; 4:53-58.
8. Bugat R, Bataillard A, Lesimple T, et al. Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site. Br J Cancer 2003; 89(suppl 1):S59-S66.
9. Holmes FF, Fouts TL. Metastatic cancer of unknown primary site. Cancer 1970; 26:816-820.
10. Stewart J, Tattersall M, Woods R, Fox R. Unknown primary adenocarcinoma: incidence of overinvestigation and natural history. Br Med J 1979; 1:1530-1533.
11. Smith P, Krementz E, Chapman W. Metastatic cancer without a detectable primary site. Am J Surg 1967; 113:633-637.
12. Probert J. Secondary carcinoma in cervical lymph nodes with an occult primary tumor. A review of 61 patients including their response to radiotherapy. Clin Radiol 1970; 21:211-218.
13. Pico J, Frias Z, Bosch A. Cervical lymph node metastases from carcinoma of undetermined origin. Am J Roentgenol 1971; 111:95-102.
14. Lleander V, Goldstein G, Horsley J. Chemotherapy in the management of metastatic cancer of unknown primary site. Oncology 1972; 26:265-270.
15. Moertel C, Reitemeier R, Schutt A, et al. Treatment of the patient with adeno-carcinoma of unknown origin. Cancer 1972; 30:1469-1472.
16. Didolkar M, Fanous N, Elias E, et al. Metastatic carcinomas from occult primary tumors. A study of 254 patients. Ann Surg 1977; 186:625-630.
17. Snyder R, Mavligit G, Valdivieso M. Adenocarcinoma of unknown primary site: a clinicopathological study. Med Pediatr Oncol 1979; 6:289-294.
18. Steckel R, Kagan R. Diagnostic persistence in working-up metastatic cancer with an unknown primary site. Radiology 1980; 134:367-369.
19. Shildt R, Kennedy P, Chen T, et al. Management of patients with metastatic adenocarcinoma of unknown origin: a Southwest Oncology Group Study. Cancer Treat Rep 1983; 67:77-79.
20. Greco FA, Hainsworth JD. Cancer of unknown primary site. In: DeVita TV, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 4th ed. 1997:2423-2443.
21. Richardson RL, Greco FA, Wolff S, et al. Extragonadal germ cell malignancy: value of tumor markers in metastatic carcinoma in young men. Proc Am Soc Clin Oncol 1979; 20:204.
22. Fox RM, Woods RL, Tattersall MHN, McGovern VJ. Undifferentiated carcinoma in young men: the atypical teratoma syndrome. Lancet 1979; I: 1316-1318.
23. Richardson RL, Schoumacher R, Oldham RK, et al. The unrecognized extra-gonadal germ cell syndrome. Ann Intern Med 1981; 94:181-189.
24. Greco FA, Vaughn WK, Hainsworth JD. Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome. Ann Intern Med 1986; 142:547-553.
25. Hainsworth JD, Wright EP, Gray GF, Greco FA. Poorly differentiated carcinoma of unknown primary site: correlation of light microscopic findings with response to cisplatin-based combination chemotherapy. J Clin Oncol 1987; 5:1275-1280.
26. Hainsworth JD, Johnson DH, Greco FA. Poorly differentiated neuroendocrine carcinoma of unknown primary site: a newly recognized clinicopathologic entity. Ann Intern Med 1988; 109:364-371.
27. Van der Gaast A, Verweij J, Henzen-Logmans SC, et al. Carcinoma ofunknown primary: identification of a treatable subset. Ann Oncol 1990; 1:119-122.
28. Currow DC, Findlay M, Cox K, Harnett PR. Elevated germ cell markers in carcinoma of uncertain primary site do not predict response to platinum based chemotherapy. Eur J Cancer 1996; 32A:2357-2359.
29. Ellerbroek N, Holmes F, Singletary E, Evans H, Oswald M, Mc Neese M. Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin. Cancer 1990; 66:1461-1467.
30. Foroudi F, Tiver KW. Occult breast carcinoma presenting as axillary metastases. Int J Radiat Oncol Biol Phys 2000; 47:143-147.
31. Vlastos G, Jean ME, Mizza AN, et al. Feasibility of breast presentation in the treatment ofoccult primary carcinoma presenting with axillary metastases. Ann Surg Oncol 2001; 8:425-431.
32. Jackson B, Scott-Conner C, Moulder J. Axillary metastases from occult breast carcinoma: diagnosis and management. Am Surg 1995; 61:431-434.
33. Grau C, Johansen LV, Jakobsen J, Geertsen P, Andersen E, Jensen BB. Cervical lymph node metastases from unknown primary tumors. Results from a national survey by the Danish Society for Head and Neck Oncology. Radiother Oncol 2000; 55:121-129.
34. Nieder C, Gregoire V, Ang KK. Cervical lymph node metastases from occult squamous cell carcinoma: cut down a tree to get an apple? Int J Radiat Oncol Biol Phys 2001; 50:727-733.
35. Guarischi A, Keane TJ, Elhakim T. Metastatic inguinal nodes from an unknown primary neoplasm. A review of 56 cases. Cancer 1987; 19:572-577.
36. Casciato DA, Tabbarah HJ. Metastases of unknown origin. In: Haskell CM, ed. Cancer Treatment. 3rd ed. WB Saunders, 1990:798-814.
37. Shmueli E, Leider-Trejo L, Schwartz I, Aderka D, Inbar M. Primary papillary serous carcinoma of the peritoneum in a man. Ann Oncol 2001; 12:563-567.
38. Shah AI, Jayram L, Gani OS, et al. Papillary serous carcinoma of the peritoneum in a man: a case report. Cancer 1998; 82(5):860-866.
39. Chen KT, Flam MS. Peritoneal papillary serous carcinoma with long-term survival. Cancer 1986; 58:1371-1373.
40. Dalrymple JC, Bannatyne P, Russel P, et al. Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases. Cancer 1989; 64:110-115.
41. Ransom DT, Patel SR, Keeney GL, Malkasian GD, Edmonson JH. Papillary serous carcinoma of the peritoneum. Cancer 1990; 66:1091-1094.
42. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68:227-233.
43. Tell DT, Khoury JM, Taylor HG, Veasey SP. Atypical metastasis from prostate cancer: clinical utility of the immunoperoxidase technique for prostate specific antigen. JAMA 1985; 253:3574-3579.
44. Gentile PS, Carloss HW, Huang TY, Yam LT, Lam WK. Disseminated prostatic carcinoma simulating primary lung cancer. Cancer 1988; 62:711-714.
45. Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 1994; 12:1272-1280.
46. Ayoub JP, Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JC. Unknown primary tumors metastatic to liver. J Clin Oncol 1998; 16:2105-2112.
47. Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol 1992; 10:912-922.
48. Kambhu SA, Kelsen DP, Fiore J, et al. Metastatic adenocarcinomas of unknown primary site: prognostic variables and treatment results. Am J Clin Oncol 1990; 13:55-60.
49. Van der Gaast A, Verweij J, Planting AST, et al. Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site. J Clin Oncol 1995; 13:1720-1725.
50. Culine S, Kramar A, Saghatchian M, et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 2002; 20:4679-4683.
51. Sadeghi B, Arvieux C, Glehen D, et al. Peritoneal carcinomatosis from non-gynecologic malignancies. Results of the EVOCAPE 1 multicentric prospective study. Cancer 2000; 88:358-363.
52. Le Chevalier T, Smith FP, Caille P, Costans JP, Rouesse JG. Sites of primary malignancies in patients presenting with cerebral metastases. A review of 120 cases. Cancer 1985; 56:880-882.
53. Nguyen LN, Maor MH, Oswald MJ. Brain metastases as the only manifestation of an undetected primary tumor. Cancer 1998; 83:2181-2184.
54. Wen PY, Loeffler JS. Management of brain metastases. Oncology 1999; 13: 941-954.